Log in to search using one of your social media accounts:

 

How to facilitate laparoscopy in obese oncologic patients - 10 steps towards successful surgery.
PMID: 29428255 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Kemp MM, Gałczyński K, Botchorishvili R, Bourdel N Tags: Gynecol Oncol Source Type: research

Early stage mucinous ovarian cancer: A review.
Abstract Mucinous ovarian carcinomas (MOCs) are an uncommon subset of epithelial neoplasms, both clinically and molecularly distinct from other ovarian cancers. Pathologic diagnosis proves challenging, and metastatic disease from other sites-especially the digestive tract-must be excluded. Fortunately, most patients are diagnosed at an early stage of disease and often present with large, unilateral adnexal masses. Survival for patients with stage IA disease approaches over 90%, and surgery alone is sufficient. Patients with stage IB-II disease should receive adjuvant treatment but the specific regimen is controver...
Source: Gynecologic Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Crane EK, Brown J Tags: Gynecol Oncol Source Type: research

γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
CONCLUSIONS: Our data reveals an important role of GGCT in regulating EMT and progression of HGSC, providing a valuable prognostic marker and potential target for treatment of HGSC patients. PMID: 29429592 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Li Y, Wu T, Wang Y, Yang L, Hu C, Chen L, Wu S Tags: Gynecol Oncol Source Type: research

An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
CONCLUSIONS: There was a reduction in risk of endometrial cancer among statin users at baseline but not in time-dependent models. Pravastatin use was associated with an increased risk of ovarian cancer. Analyses of larger numbers of cases are needed to evaluate these findings. PMID: 29422345 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 5, 2018 Category: Cancer & Oncology Authors: Desai P, Wallace R, Anderson ML, Howard BV, Ray RM, Wu C, Safford M, Martin LW, Rohan T, Manson JE, Simon MS Tags: Gynecol Oncol Source Type: research

Bone loss in women with BRCA1 and BRCA2 mutations.
CONCLUSION: Bone loss is common in women with BRCA mutations who undergo RRSO. PMID: 29422346 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 5, 2018 Category: Cancer & Oncology Authors: Powell CB, Alabaster A, Stoller N, Armstrong MA, Salyer C, Hamilton I, Raine-Bennett T Tags: Gynecol Oncol Source Type: research

Ongoing strategies and updates on pain management in gynecologic oncology patients.
Abstract The opioid crisis in the United States has been declared a public health emergency. Various governmental agencies, cancer care organizations and the Centers for Disease Control and Prevention have issued guidelines in hopes of managing this crisis. Curbing over-prescription of opioids by medical professionals has been a central theme in many of these guidelines. Gynecologic oncologists encounter patients with a variety of pain sources, including acute pain secondary to the underlying malignancy or surgical procedures as well as chronic pain related to the malignancy and the sequelae of treatments rendered...
Source: Gynecologic Oncology - February 3, 2018 Category: Cancer & Oncology Authors: Hacker KE, Reynolds RK, Uppal S Tags: Gynecol Oncol Source Type: research

Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
CONCLUSION: Application of a quality improvement process to create a Genetics Referral Toolkit increased the genetic counseling referral rate in patients with a new diagnosis of EOC. The majority of patients who were referred completed genetics consultation and elected genetic testing. PMID: 29402500 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 3, 2018 Category: Cancer & Oncology Authors: Swanson CL, Kumar A, Maharaj JM, Kemppainen JL, Thomas BC, Weinhold MR, Slaby KM, Mara KC, Wick MJ, Bakkum-Gamez JN Tags: Gynecol Oncol Source Type: research

Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer.
CONCLUSION: The 3-year results demonstrated that TAUS-guided brachytherapy is feasible and associated with excellent tumor control/toxicity rates in cervical cancer. PMID: 29398070 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Tharavichitkul E, Chakrabandhu S, Klunklin P, Onchan W, Jia-Mahasap B, Wanwilairat S, Tippanya D, Jayasvasti R, Sripan P, Galalae RM, Chitapanarux I Tags: Gynecol Oncol Source Type: research

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Abstract OBJECTIVES: Aberrant homeobox (HOX) gene expression is reported in high-grade serous ovarian carcinoma (HGSOC), however, its prognostic significance remains unclear. METHODS: HOX genes associated with progression-free survival (PFS) in a discovery cohort of primary HGSOC samples with RNA sequencing data, and those previously reported to be associated with clinical outcomes, were selected for qPCR testing in an independent training cohort of primary HGSOC samples (n=71). A prognostic model for PFS was developed using univariate and multivariate Cox regression. Patients were stratified into risk groups...
Source: Gynecologic Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK Tags: Gynecol Oncol Source Type: research

Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
CONCLUSION: The ROCA test can improve the detection of early ovarian cancer but is not practical for screening in an average-risk population. We predict the ROCA test will reduce overall ovarian cancer mortality by 6% to 9% but at a substantial cost. For ROCA to be practical, the cost would need to be reduced ten-fold and would have only a marginal impact on mortality from ovarian cancer. This model supports the FDA's criticism of the ROCA test. Ovarian cancer screening may reduce mortality from ovarian cancer but is not cost effective. PMID: 29398069 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Naumann RW, Brown J Tags: Gynecol Oncol Source Type: research

Nonmetastatic Excised Gestational Choriocarcinoma: To Treat or Not to Treat.
PMID: 29406249 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Strohl AE, Lurain JR Tags: Gynecol Oncol Source Type: research

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Abstract Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy. The mechanisms of action of niraparib include inhibition of PARP enzymatic activity as well as increased formation of PARP-DNA complexes through "trapping" the PARP enzyme on damaged DNA. Phase I and III studies have demonstrated activity an...
Source: Gynecologic Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Moore KN, Mirza MR, Matulonis UA Tags: Gynecol Oncol Source Type: research

Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Abstract As precision medicine has become a focus in oncology in recent years, many targeted and biologic agents are being used along with or in place of traditional cytotoxic chemotherapy. As these drugs have been developed and some have received FDA approval, we have gained substantial data about the adverse event profiles. However, the management and approach to the toxicities incurred and subsequent complications are often not well understood, especially for physicians who have a varied clinical practice. The purpose of this review is to provide an overview of the frequency and types of adverse events and appr...
Source: Gynecologic Oncology - January 30, 2018 Category: Cancer & Oncology Authors: Gunderson CC, Matulonis U, Moore KN Tags: Gynecol Oncol Source Type: research

A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial.
DISCUSSION: Intraoperative application of collagen-fibrin patches to the pelvic side walls does not reduce the incidence of symptomatic lymphoceles in women with gynecologic malignancies undergoing pelvic lymphadenectomy. PMID: 29395308 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 30, 2018 Category: Cancer & Oncology Authors: Grimm C, Polterauer S, Helmy-Bader S, Zikan M, Cibula D, Heitz F, Harter P, Giese A, Reinthaller A, Tempfer C Tags: Gynecol Oncol Source Type: research

Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things.
CONCLUSIONS: The SGO COR has proven the feasibility of developing a functional gynecologic cancer registry, with high uptake, rapid accrual, and ability to investigate topics of quality and outcome using the COR. PMID: 29395312 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 30, 2018 Category: Cancer & Oncology Authors: Dewdney SB, Dancisak AC, Lachance JA, Grendys EC, Dowdy SC, Powell M, Schorge JO Tags: Gynecol Oncol Source Type: research

Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis.
Abstract OBJECTIVE: To identify the baseline sleep patterns of endometrial cancer survivors and examine the impact of a physical activity intervention on their sleep quality via retrospective secondary analysis. METHODS: Early-stage endometrial cancer survivors participated in a 6-month single-arm exercise intervention using printed materials, telephone-based counseling, and pedometers to encourage adherence to exercise guidelines. Participants completed questionnaires evaluating their sleep (PSQI), physical activity (CHAMPS), quality of life (SF-36), and stress (PSS) at baseline and study completion. RE...
Source: Gynecologic Oncology - January 30, 2018 Category: Cancer & Oncology Authors: Armbruster SD, Song J, Gatus L, Lu KH, Basen-Engquist KM Tags: Gynecol Oncol Source Type: research

ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
Abstract OBJECTIVE: In recent years, the Wnt signalling pathway and the ROR1 and ROR2 receptors have been implicated in a range of gynecological cancers. These receptors have been described as prospective therapeutic targets, and this study investigated such potential in an endometrial cancer context. METHOD: Immunohistochemistry for ROR1 and ROR2 was performed in a patient cohort, and expression was correlated with clinicopathological parameters including type, stage, grade, myometrial invasion, lymphovascular involvement, patient age and survival. The functional role of these receptors in endometrial cancer...
Source: Gynecologic Oncology - January 29, 2018 Category: Cancer & Oncology Authors: Henry CE, Llamosas E, Daniels B, Coopes A, Tang K, Ford CE Tags: Gynecol Oncol Source Type: research

Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
CONCLUSION: Distinct HR expression profiles define subgroups associated with overall outcome in patients that are exposed to neoadjuvant chemotherapy and not only chemotherapy-naïve patients. PMID: 29395310 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 29, 2018 Category: Cancer & Oncology Authors: Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH Tags: Gynecol Oncol Source Type: research

Secondary debulking surgery for para-aortic nodal recurrence in endometrial cancer requiring circumferential resection of the inferior vena cava.
PMID: 29395305 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 27, 2018 Category: Cancer & Oncology Authors: Kato K, Okamoto S, Ota E, Takeshima N Tags: Gynecol Oncol Source Type: research

The role of physical activity in breast and gynecologic cancer survivorship.
Abstract Physical activity improves physical functioning, cancer-related symptoms, and quality of life in cancer survivors, and is beneficial across all phases of survivorship. Observational studies suggest that high levels of physical activity may also improve cancer outcomes such as survival, but randomized controlled trials of exercise interventions in oncology patients with survival outcomes as a primary endpoint are needed and ongoing. This review focuses on the role of physical activity in breast and gynecologic cancer survivorship, based on the available evidence. It discusses specific guidelines for exerci...
Source: Gynecologic Oncology - January 27, 2018 Category: Cancer & Oncology Authors: Pennington KP, McTiernan A Tags: Gynecol Oncol Source Type: research

Myosin 1b promotes cell proliferation, migration, and invasion in cervical cancer.
CONCLUSION: Taken together, our data suggested a potential role of Myo1b in cervical carcinogenesis and tumor progression and provided novel insights into the mechanism of how this factor promotes cell proliferation, migration, and invasion in CC cells. PMID: 29395313 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 27, 2018 Category: Cancer & Oncology Authors: Zhang HR, Lai SY, Huang LJ, Zhang ZF, Liu J, Zheng SR, Ding K, Bai X, Zhou JY Tags: Gynecol Oncol Source Type: research

Patterns of palliative care referral in ovarian cancer: A single institution 5  year retrospective analysis.
Patterns of palliative care referral in ovarian cancer: A single institution 5 year retrospective analysis. Gynecol Oncol. 2018 Jan 27;: Authors: Nitecki R, Diver EJ, Kamdar MM, Boruta DM, Del Carmen MC, Clark RM, Goodman A, Schorge JO, Growdon WB Abstract BACKGROUND: The American Society of Clinical Oncology recommends that patients with advanced cancer receive dedicated palliative care services early in their disease course. This investigation serves to understand how palliative care services are utilized for ovarian cancer patients in a tertiary referral center. METHODS: We conducted a retro...
Source: Gynecologic Oncology - January 27, 2018 Category: Cancer & Oncology Authors: Nitecki R, Diver EJ, Kamdar MM, Boruta DM, Del Carmen MC, Clark RM, Goodman A, Schorge JO, Growdon WB Tags: Gynecol Oncol Source Type: research

Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
Abstract OBJECTIVE: Many high-grade serous carcinomas initiate in fallopian tubes as serous tubal intraepithelial carcinoma (STIC), a microscopic lesion identified with specimen processing according to the Sectioning and Extensive Examination of the Fimbria protocol (SEE-Fim). Given that the tubal origin of these cancers was recently recognized, we conducted a survey of pathology practices to assess processing protocols that are applied to gynecologic surgical pathology specimens in clinical contexts in which finding STIC might have different implications. METHODS: We distributed a survey electronically to th...
Source: Gynecologic Oncology - January 25, 2018 Category: Cancer & Oncology Authors: Samimi G, Trabert B, Duggan MA, Robinson JL, Coa KI, Waibel E, Garcia E, Minasian LM, Sherman ME Tags: Gynecol Oncol Source Type: research

Tumor associated macrophages in gynecologic cancers.
Abstract The complex tumor microenvironment in gynecologic cancers plays a major role in modulating anti-tumor immune responses. The interaction of cancer cells with the diverse spectrum of immune effector cells has an important impact on the efficacy of standard chemotherapy and novel immunotherapy approaches. In this review, we specifically focus on the role of macrophages in ovarian, endometrial and cervical cancers. We discuss the origins of macrophages and their polarization state dictated by the microenvironment's cues. Within the tumor niche, tumor-associated macrophages (TAMs) promote tumor growth and medi...
Source: Gynecologic Oncology - January 22, 2018 Category: Cancer & Oncology Authors: Krishnan V, Schaar B, Tallapragada S, Dorigo O Tags: Gynecol Oncol Source Type: research

SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm.
Cibula D Abstract OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastase...
Source: Gynecologic Oncology - January 21, 2018 Category: Cancer & Oncology Authors: Dostálek L, Zikan M, Fischerova D, Kocian R, Germanova A, Frühauf F, Dusek L, Slama J, Dundr P, Nemejcova K, Cibula D Tags: Gynecol Oncol Source Type: research

The NCI-MATCH trial and precision medicine in gynecologic cancers.
Abstract The Precision Medicine Initiative is a National Cancer Institute (NCI) driven interdisciplinary collaborative effort to test the feasibility of trials incorporating genomic profiling when choosing patient therapies. The goal of the initiative is to generate the scientific evidence needed to move the concept of precision medicine, or targeted therapy, into clinical practice. The rapid development and widespread availability of next generation sequencing provides access to information regarding an individual's tumor at various times during the course of their disease. Translating the aberrations specific to...
Source: Gynecologic Oncology - January 20, 2018 Category: Cancer & Oncology Authors: Barroilhet L, Matulonis U Tags: Gynecol Oncol Source Type: research

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
CONCLUSIONS: Veliparib plus carboplatin/gemcitabine is tolerated, with a safety profile similar to carboplatin and gemcitabine alone. Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancer patients with germline BRCA mutations. Trial registration ID: NCT01063816. PMID: 29352572 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 15, 2018 Category: Cancer & Oncology Authors: Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP Tags: Gynecol Oncol Source Type: research

Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.
Abstract OBJECTIVES: Minimally invasive surgery (MIS) is a quality measure for endometrial cancer (EC) established by the Society of Gynecologic Oncology and the American College of Surgeons. Our study objective was to assess the proportion of EC cases performed by MIS at National Comprehensive Cancer Network (NCCN) centers and evaluate perioperative outcomes. METHODS: A retrospective cohort study of women who underwent surgical treatment for EC from 2013 to 2014 was conducted at four NCCN centers. Multivariable mixed logistic regression models analyzed factors associated with failure to perform MIS and perio...
Source: Gynecologic Oncology - January 12, 2018 Category: Cancer & Oncology Authors: Bergstrom J, Aloisi A, Armbruster S, Yen TT, Casarin J, Leitao MM, Tanner EJ, Matsuno R, Machado KK, Dowdy SC, Soliman PT, Wethington SL, Stone RL, Levinson KL, Fader AN Tags: Gynecol Oncol Source Type: research

Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy.
CONCLUSIONS: High-dose volume-directed radiotherapy achieves a high rate of local control with low risk of serious long-term toxic effects in patients with vulvar squamous cell carcinoma and grossly involved inguinal lymph nodes. PMID: 29336837 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 11, 2018 Category: Cancer & Oncology Authors: Stecklein SR, Frumovitz M, Klopp AH, Gunther JR, Eifel PJ Tags: Gynecol Oncol Source Type: research

Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
CONCLUSIONS: Our results suggest that both lower and higher birth weights were associated with increased ovarian cancer risk and associations were particularly strong for serous ovarian cancer, the most common subtype. Birth weight was not associated with most types of endometrial cancer. PMID: 29331371 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 10, 2018 Category: Cancer & Oncology Authors: Trabert B, Aarestrup J, Ulrich LG, Wentzensen N, Sørensen TIA, Baker JL Tags: Gynecol Oncol Source Type: research

Cancer care delivery research in gynecologic oncology.
PMID: 29331372 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 10, 2018 Category: Cancer & Oncology Authors: Shalowitz DI, Cohn DE Tags: Gynecol Oncol Source Type: research

Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
CONCLUSION: Here we identify CD11b as a novel target, which selectively induces cytotoxicity in ovarian cancer cells. PMID: 29329880 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 9, 2018 Category: Cancer & Oncology Authors: Saed GM, Fletcher NM, Diamond MP, Morris RT, Gomez-Lopez N, Memaj I Tags: Gynecol Oncol Source Type: research

Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery.
Abstract The incidence of endometrial cancer (EC) is steadily increasing due in large part to an aging world population and rise in rates of obesity. Patients with obesity and advancing age can be seen as vulnerable populations, as they are both often subject to physician bias regarding surgical choices and assumptions regarding long-term outcomes. As we operate on an older and/or obese patient population, it is increasingly important that we adopt peri-operative management strategies and surgical techniques to best serve this complex patient population. Careful orchestration pre-, intra- and postoperatively is ke...
Source: Gynecologic Oncology - January 9, 2018 Category: Cancer & Oncology Authors: Hagemann AR, McCourt CK, Varaday SS, Moore KN Tags: Gynecol Oncol Source Type: research

Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
CONCLUSIONS: The presence of residual lymph node after chemoradiotherapy was associated with worse survival in patients with node-positive cervical cancer. PMID: 29329882 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 9, 2018 Category: Cancer & Oncology Authors: Park SH, Cheon H, Chong GO, Jeong SY, Lee JE, Kang MK, Kim MY, Lee JW, Park J, Kim JC Tags: Gynecol Oncol Source Type: research

Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer.
Abstract OBJECTIVE: In cervical cancer patients, dose-volume relationships have been demonstrated for tumor and organs-at-risk, but not for pathologic nodes. The nodal control probability (NCP) according to dose/volume parameters was investigated. MATERIAL AND METHODS: Patients with node-positive cervical cancer treated curatively with external beam radiotherapy (EBRT) and image-guided brachytherapy (IGABT) were identified. Nodal doses during EBRT, IGABT and boost were converted to 2-Gy equivalent (α/β = 10 Gy) and summed. Pathologic nodes were followed individually from diagnosis to relapse....
Source: Gynecologic Oncology - January 8, 2018 Category: Cancer & Oncology Authors: Bacorro W, Dumas I, Escande A, Gouy S, Bentivegna E, Morice P, Haie-Meder C, Chargari C Tags: Gynecol Oncol Source Type: research

Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
ich R Abstract OBJECTIVE: To profile long non-coding RNA (lncRNA) expression at the various anatomic sites of high-grades serous carcinoma (HGSC) and in effusion-derived exosomes. METHODS: LncRNA profiling was performed on 60 HGSC specimens, including 10 ovarian tumors, 10 solid metastases and 10 malignant effusions, as well as exosomes from 30 effusion supernatants. Anatomic site-related expression of ESRG, Link-A, GAS5, MEG3, GATS, PVT1 H19, Linc-RoR, HOTAIR and MALAT1 was validated by quantitative PCR and assessed for clinical relevance in a series of 77 HGSC effusions, 40 ovarian carcinomas, 21 solid meta...
Source: Gynecologic Oncology - January 5, 2018 Category: Cancer & Oncology Authors: Filippov-Levy N, Cohen-Schussheim H, Tropé CG, Hetland Falkenthal TE, Smith Y, Davidson B, Reich R Tags: Gynecol Oncol Source Type: research

Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
PMID: 29307453 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 5, 2018 Category: Cancer & Oncology Authors: Matsuoka A, Tate S, Nishikimi K, Shozu M Tags: Gynecol Oncol Source Type: research

Racial disparities in young women with endometrial cancer.
Abstract OBJECTIVE: Although racial disparities in treatment and outcome for endometrial cancer are well recognized, little work has explored disparities in young women. We performed a population-based analysis to compare survival between black and white women with endometrial cancer at
Source: Gynecologic Oncology - January 4, 2018 Category: Cancer & Oncology Authors: Mukerji B, Baptiste C, Chen L, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD Tags: Gynecol Oncol Source Type: research

Patient Reported Outcomes: Recent Successes and Future Opportunities.
PMID: 29304953 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 1, 2018 Category: Cancer & Oncology Authors: Melamed A, Wright AA Tags: Gynecol Oncol Source Type: research

The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
CONCLUSION: Our data indicate that the risk of lymph node involvement in patients with a preoperative diagnosis of "AH-only" is null. Lymph node assessment could be omitted in those patients. Conversely this risk is significant in patients with "AH - cannot rule out cancer". SLN mapping could be a valuable staging procedure in these patients. PMID: 29290489 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 28, 2017 Category: Cancer & Oncology Authors: Touhami O, Grégoire J, Renaud MC, Sebastianelli A, Grondin K, Plante M Tags: Gynecol Oncol Source Type: research

Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
CONCLUSIONS: Endometrial cancer survivors were at higher risk for many genitourinary outcomes compared to women from the general population. This study presents evidence suggesting the necessity of increased monitoring and counseling for genitourinary disorders for endometrial cancer patients both immediately after treatment cessation and for years afterwards. PMID: 29289418 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 27, 2017 Category: Cancer & Oncology Authors: Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Hanson HA, Wu YP, Stanford J, Werner TL, Setiawan VW, Hashibe M Tags: Gynecol Oncol Source Type: research

ERBB2 mutation: A promising target in non-squamous cervical cancer.
CONCLUSIONS: This study provided a promising rationale for the clinical investigation of tyrosine kinase inhibitors for the treatment of cervical cancer with ERBB2 mutations. Patients with non-squamous cell carcinomas have priority as candidates for ERBB2-targeted therapy. Concurrent PIK3CA/RAS mutations should be considered in the design of clinical trials. PMID: 29279289 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 23, 2017 Category: Cancer & Oncology Authors: Xiang L, Jiang W, Ye S, He T, Pei X, Li J, Chan DW, Ngan HYS, Li F, Tao P, Shen X, Zhou X, Wu X, Yang G, Yang H Tags: Gynecol Oncol Source Type: research

Racial/ethnic differences in HPV 16/18 genotypes and integration status among women with a history of cytological abnormalities.
CONCLUSIONS: While HPV16 and 18 infections were less prevalent among Hispanic and black women compared to whites, their HPV16 DNA was more likely to be present in a fully integrated state. This could potentially contribute to the higher rates of abnormal cytology and cervical dysplasia observed among Hispanic and black women. PMID: 29276057 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Montealegre JR, Peckham-Gregory EC, Marquez-Do D, Dillon L, Guillaud M, Adler-Storthz K, Follen M, Scheurer ME Tags: Gynecol Oncol Source Type: research

Robot-assisted anterior pelvic exenteration in vulvovaginal malignant melanoma.
CONCLUSION: rAPE with ileal conduit urinary diversion for treatment of vulvovaginal malignant melanoma is feasible (Fig. 1). PMID: 29276058 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Kim SI, Lee S, Jeong CW, Kim HS Tags: Gynecol Oncol Source Type: research

Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis.
CONCLUSION: Racial disparities in endometrial cancer survival are predominantly attributable to increased advanced stage, high-grade and aggressive histologic subtype tumors and differential use of surgery in Black women. Intensified surgical and radiation treatment is associated with improved survival, raising questions about treatment adaptations that may potentially reduce survival disparities. PMID: 29276059 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Sud S, Holmes J, Eblan M, Chen R, Jones E Tags: Gynecol Oncol Source Type: research

Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas.
CONCLUSIONS: Seventy to 75% of all vaginal and vulvar cancers are due to HPV infections and mean medical costs associated with these cancers are substantial. These data will serve as key cost parameters in the economic evaluation of HPV vaccination dissemination and estimation of the long-term net economic benefit of promoting HPV vaccination. PMID: 29274828 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 20, 2017 Category: Cancer & Oncology Authors: Fu S, Lairson DR, Chan W, Wu CF, Ramondetta L Tags: Gynecol Oncol Source Type: research

Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications.
CONCLUSION: The high feasibility, the absence of intraoperative complications and the low risk of lymphatic complications supports implementing detection of sentinel lymph nodes in low-risk endometrial cancer patients. Given that available preliminary data on sensitivity and false negative rates in high-risk patients are confirmed in further studies, we also believe that the reduction in lymphatic complications and operative time strongly motivates the sentinel lymph node concept in high-risk endometrial cancer. PMID: 29273307 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 20, 2017 Category: Cancer & Oncology Authors: Geppert B, Lönnerfors C, Bollino M, Persson J Tags: Gynecol Oncol Source Type: research

Robotic hysterectomy and pelvic lymphadenectomy without Trendelenburg position (BMI 36).
PMID: 29273306 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Fornalik H, Fornalik N Tags: Gynecol Oncol Source Type: research

Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
CONCLUSIONS: In the short-term, NACT is a cost-effective alternative compared to PCS in women with AEOC. These results may translate to longer term cost-effectiveness; however, data from randomized control trials continues to mature. PMID: 29273308 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Tran AQ, Erim DO, Sullivan SA, Cole AL, Barber EL, Kim KH, Gehrig PA, Wheeler SB Tags: Gynecol Oncol Source Type: research

Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
Abstract OBJECTIVES: A previous study has suggested the benefit of sub-renal vein radiotherapy (SRVRT) for pelvic lymph node (PLN)-positive cervical cancer. In order to better select patients for SRVRT, this study aimed to evaluate the value of a risk-based radiation field based on PLN location and number in PLN-positive cervical cancer. METHODS: We reviewed 198 patients with FIGO stage IB2-IVA cervical cancer, positive PLNs, and negative para-aortic lymph nodes (PALNs) from 2004 to 2015 at two tertiary centers. All patients underwent pelvic radiotherapy (PRT) or SRVRT with IMRT. The SRVRT extended the PRT fi...
Source: Gynecologic Oncology - December 18, 2017 Category: Cancer & Oncology Authors: Lee J, Lin JB, Chang CL, Sun FJ, Wu MH, Jan YT, Chen YJ Tags: Gynecol Oncol Source Type: research